Global Angina Pectoris Drugs Market Size study, by Type (Stable Angina, Unstable Angina), by Drug Class (Beta Blockers, Anticoagulants), by Distribution Channel, and Regional Forecasts 2022-2032

Description

The Global Angina Pectoris Drugs Market is valued at approximately USD 11.37 billion in 2023 and is projected to grow steadily at a compound annual growth rate (CAGR) of 4.00% over the forecast period from 2024 to 2032. Angina pectoris, a symptomatic manifestation of myocardial ischemia, continues to be a pressing cardiovascular concern, particularly among aging populations and individuals with chronic lifestyle disorders. With healthcare systems worldwide intensifying their focus on reducing cardiovascular morbidity and mortality, pharmacological interventions for angina are receiving renewed attention. The market is witnessing a clinical shift from traditional monotherapy to combination regimens that leverage synergistic effects of anti-anginal agents such as beta blockers, calcium channel blockers, and newer anticoagulants. This progression is underpinned by an increase in guideline-directed medical therapy and heightened physician awareness surrounding risk stratification and patient-specific treatment algorithms.

The steady rise in the prevalence of coronary artery disease, sedentary lifestyles, tobacco consumption, and diabetes is fuelling demand for angina therapeutics across both high-income and emerging economies. In tandem, improvements in clinical infrastructure and diagnostic capabilities have enhanced the early detection of stable and unstable angina forms, ensuring timely therapeutic intervention. Leading pharmaceutical giants are investing substantially in the development of novel drug classes that not only manage symptoms but also improve long-term cardiovascular outcomes. Moreover, the integration of digital health platforms and remote monitoring solutions is enabling better medication adherence, further strengthening market potential. However, despite robust progress, cost-intensive branded therapies and adverse drug interactions in polypharmacy scenarios remain significant hurdles-especially in low- and middle-income countries.

Technological advancements and strategic collaborations among pharmaceutical companies are creating new avenues for drug innovation and distribution. Biosimilars and generic formulations of commonly prescribed agents like beta blockers and anticoagulants are expanding market access by offering affordable options to underserved patient groups. At the same time, the emergence of data-driven clinical decision-making is refining prescription behaviors, reducing instances of therapeutic redundancy, and optimizing patient outcomes. Regulatory bodies are also playing a pivotal role by expediting drug approvals and updating treatment guidelines to reflect evidence-based innovations, thereby fostering a more agile and patient-centric treatment landscape.

Regionally, North America leads the global angina drugs market, propelled by a sophisticated healthcare system, high disease burden, and early adoption of advanced treatment protocols. The U.S. continues to dominate with robust R&D activities, frequent product launches, and favorable reimbursement frameworks. Europe trails closely, benefitting from increased public health expenditure and a strong emphasis on preventive cardiovascular care. Meanwhile, Asia Pacific is expected to grow at the fastest pace due to rising healthcare investments, a surging elderly population, and growing cardiovascular health awareness in countries like China, India, and Japan. Latin America and the Middle East & Africa, though still developing markets, are demonstrating promise through evolving regulatory frameworks and international pharmaceutical collaborations.

Major market player included in this report are:

AstraZeneca PLC
Bayer AG
Pfizer Inc.
Novartis AG
Sanofi
Merck & Co., Inc.
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Abbott Laboratories
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Eli Lilly and Company

The detailed segments and sub-segment of the market are explained below:

By Type

Stable Angina
Unstable Angina

By Drug Class

Beta Blockers
Anticoagulants

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Angina Pectoris Drugs Market Executive Summary

1.1. Global Angina Pectoris Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Drug Class
- 1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Angina Pectoris Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Patient's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Patient Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Angina Pectoris Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Coronary Artery Disease
- 3.1.2. Shift to Combination Therapy Regimens
- 3.1.3. Increasing Guideline-Directed Medical Therapy Adoption
3.2. Market Challenges
- 3.2.1. High Cost of Branded Anti-Anginal Agents
- 3.2.2. Polypharmacy-Related Adverse Interactions
- 3.2.3. Limited Penetration in Low-and Middle-Income Countries
3.3. Market Opportunities
- 3.3.1. Growth of Biosimilars and Generics
- 3.3.2. Integration of Digital Health and Remote Monitoring
- 3.3.3. Expansion of Preventive Cardiology Programs

Chapter 4. Global Angina Pectoris Drugs Market Industry Analysis

4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Forces
- 4.1.7. Porter's Five Forces Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Angina Pectoris Drugs Market Size & Forecasts by Type 2022-2032

5.1. Segment Dashboard
5.2. Global Angina Drugs Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Stable Angina
- 5.2.2. Unstable Angina

Chapter 6. Global Angina Pectoris Drugs Market Size & Forecasts by Drug Class 2022-2032

6.1. Segment Dashboard
6.2. Global Angina Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Beta Blockers
- 6.2.2. Anticoagulants

Chapter 7. Global Angina Pectoris Drugs Market Size & Forecasts by Distribution Channel 2022-2032

7.1. Segment Dashboard
7.2. Global Angina Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital Pharmacies
- 7.2.2. Retail Pharmacies
- 7.2.3. Online Pharmacies

Chapter 8. Global Angina Pectoris Drugs Market Size & Forecasts by Region 2022-2032

8.1. North America Angina Drugs Market
- 8.1.1. U.S. Angina Drugs Market
  - 8.1.1.1. Type Breakdown & Forecasts, 2022-2032
  - 8.1.1.2. Drug Class Breakdown & Forecasts, 2022-2032
  - 8.1.1.3. Distribution Channel Breakdown & Forecasts, 2022-2032
- 8.1.2. Canada Angina Drugs Market
8.2. Europe Angina Drugs Market
- 8.2.1. UK Angina Drugs Market
- 8.2.2. Germany Angina Drugs Market
- 8.2.3. France Angina Drugs Market
- 8.2.4. Spain Angina Drugs Market
- 8.2.5. Italy Angina Drugs Market
- 8.2.6. Rest of Europe Angina Drugs Market
8.3. Asia Pacific Angina Drugs Market
- 8.3.1. China Angina Drugs Market
- 8.3.2. India Angina Drugs Market
- 8.3.3. Japan Angina Drugs Market
- 8.3.4. Australia Angina Drugs Market
- 8.3.5. South Korea Angina Drugs Market
- 8.3.6. Rest of Asia Pacific Angina Drugs Market
8.4. Latin America Angina Drugs Market
- 8.4.1. Brazil Angina Drugs Market
- 8.4.2. Mexico Angina Drugs Market
- 8.4.3. Rest of Latin America Angina Drugs Market
8.5. Middle East & Africa Angina Drugs Market
- 8.5.1. Saudi Arabia Angina Drugs Market
- 8.5.2. South Africa Angina Drugs Market
- 8.5.3. Rest of Middle East & Africa Angina Drugs Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Pfizer Inc.
- 9.1.2. Novartis AG
- 9.1.3. AstraZeneca PLC
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Pfizer Inc.
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Novartis AG
- 9.3.3. AstraZeneca PLC
- 9.3.4. Bayer AG
- 9.3.5. Sanofi
- 9.3.6. Merck & Co., Inc.
- 9.3.7. Bristol Myers Squibb
- 9.3.8. F. Hoffmann-La Roche Ltd.
- 9.3.9. Johnson & Johnson
- 9.3.10. Abbott Laboratories
- 9.3.11. Teva Pharmaceutical Industries Ltd.
- 9.3.12. Amgen Inc.
- 9.3.13. GlaxoSmithKline plc
- 9.3.14. Boehringer Ingelheim International GmbH
- 9.3.15. Eli Lilly and Company

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes